Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental virus therapy VAXINIA tested in advanced cancer patients

NCT ID NCT05346484

First seen Jan 10, 2026 · Last updated Jun 12, 2026 · Updated 16 times

Summary

This early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor or through a vein. The main goal was to check safety and find the best dose, but the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Corewell Health

    Grand Rapids, Michigan, 49503, United States

  • Highlands Oncology

    Springdale, Arkansas, 72762, United States

  • Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

  • NEXT Oncology

    Fairfax, Virginia, 22031, United States

  • St. Vincent's Hospital

    Fitzroy, Victoria, 3065, Australia

  • Tasman Oncology Research

    Southport, Queensland, 4215, Australia

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093-0698, United States

  • University of Arizona Cancer Center

    Tucson, Arizona, 85724-5024, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Miami

    Miami, Florida, 33136, United States

Conditions

The condition(s) this trial relates to.

bile duct neoplasm carcinoma cholangiocarcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.